ERBB2 and breast cancer: Recently, the phase 3 Palbociclib Collaborative Adjuvant Study (PALLAS trial) (press report) and monarchE95 adjuvant trials testing different CDKi’s in endocrine receptor–positive/HER2-negative breast cancer have reported results.